Health Robotics About Us
About Us
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 300 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solution. Health Robotics’ second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies 1,2] to greatly contribute to ease hospitals’ growing pressures to improve patient safety [1], increase throughput, and contain costs [1]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug [1] and diluent [1] exchange errors, improve drug potency [2], decrease other medical mistakes and sterility risks, work more efficiently [1], reduce waste and controlled substances’ diversion, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff.
________________________
[1] Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
[2] Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
________________________
[1] Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
[2] Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
Health Robotics S.r.l.
Via Altmann 9/A
39100 Bolzano
Italy
Phone: +39-0471-200372
Fax: +39-0471-200574
Health Robotics Canada Inc.
6303 Blue Lagoon Drive, Suite 310
Miami, Florida 33126, USA
Phone +1.786.566.9229
Fax +1.786.217.0133
Quality System certified UN EN ISO 9001:2008
CytoCare, i.v.STATION and i.v.SOFT are registered trademarks of Health Robotics S.r.l. You may not use these trademarks without the prior written consent of Health Robotics S.r.l.
Via Altmann 9/A
39100 Bolzano
Italy
Phone: +39-0471-200372
Fax: +39-0471-200574
Health Robotics Canada Inc.
6303 Blue Lagoon Drive, Suite 310
Miami, Florida 33126, USA
Phone +1.786.566.9229
Fax +1.786.217.0133
Quality System certified UN EN ISO 9001:2008
CytoCare, i.v.STATION and i.v.SOFT are registered trademarks of Health Robotics S.r.l. You may not use these trademarks without the prior written consent of Health Robotics S.r.l.
News
